Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | ANO1 | Q5XXA6 | 5/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 5/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2950902 | 0.92 | CYP3A4 (0.37) | CYP3A4ANO1KCNH2DGAT2 | |
| SCHEMBL2950737 | 0.90 | DGAT2 (0.41) | DGAT2 | |
| SCHEMBL3913666 | 0.87 | KCNH2 (0.35) | CYP3A4ANO1KCNH2DGAT2 | |
| SCHEMBL2942807 | 0.86 | KCNH2 (0.35) | CYP3A4KCNH2 | |
| SCHEMBL3021936 | 0.85 | CCR2 (0.36) | CYP3A4MCHR1KCNH2 | |
| SCHEMBL2948465 | 0.85 | MCHR1 (0.39) | CYP3A4MCHR1KCNH2 | |
| SCHEMBL2949641 | 0.85 | UTS2R (0.41) | CYP3A4FLT3 | |
| SCHEMBL4602736 | 0.84 | CYP3A4 (0.35) | CYP3A4KCNH2 | |
| SCHEMBL2949608 | 0.84 | CYP3A4 (0.36) | CYP3A4ANO1KCNH2 | |
| SCHEMBL2948319 | 0.83 | CYP3A4 (0.37) | CYP3A4FLT3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940782-B1 | N-PHENYL PHENYLACETAMIDE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | EP | claimed |
| EP-1940782-A1 | N-PHENYL PHENYLACETAMIDE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INIHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-09 | — | — | EP | claimed |
| WO-2007045572-A1 | N-PHENYL PHENYLACETAMIDE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INIHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-26 | — | — | WO | claimed |
| US-7754919-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2010-07-13 | — | — | US | disclosed |
| EP-1940782-B1 | N-PHENYL PHENYLACETAMIDE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | EP | disclosed |
| US-20070088015-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088015-A1 | Non-nucleoside reverse transcriptase inhibitors | SAMHD1, QTRT1, REV1 | CYP3A4 889/4885ANO1 3734/4885MCHR1 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.